Radiopharm Theranostics ADR (NASDAQ:RADX) is among the best Australian stocks to buy in 2026. Radiopharm Theranostics ADR (NASDAQ:RADX) continues to advance its clinical programs with solid results. On April 20, the company presented initial findings from an early-stage trial of its cancer drug candidate at the American Association for Cancer Research Annual Meeting.
The drug candidate, 177Lu-RAD202, is being developed as a treatment for various cancers, including breast cancer. In the Phase 1 HEAT clinical trial, 177Lu-RAD202 was evaluated in patients with advanced HER2-positive breast and urothelial cancers. These patients had been through multiple metastatic therapies before. In this trial, they received the lowest dose of 30 mCi.
In this study, 177Lu-RAD202 showed encouraging tumor uptake. It also demonstrated a favorable safety profile. With these findings, Radiopharm has been approved to advance the trial to the next dose level of 130 mCi. This dose escalation approval covers cohort 1 and cohort 2.
The company is conducting the Phase 1 HEAT study at clinical centers across Australia. It aims to complete the Phase 1 dose escalation by the end of this year.
At this point, Radiopharm has a busy clinical program, with a pipeline that includes five Phase 1 trials and one Phase 2 trial. These trials cover diverse cancer types, including lung cancer, prostate cancer, breast cancer, and brain cancer.
On April 7, Radiopharm announced a supply deal with Siemens for its brain cancer drug program. Under this deal, Siemens will manufacture and supply doses of Radiopharm’s drug candidate RAD101 for Phase 3 registrational trials in the US.
Radiopharm Theranostics ADR, headquartered in Melbourne, Australia, is a biotech focused on developing products for cancer care. It specializes in developing first-in-class radiopharmaceuticals for cancer diagnosis and treatment.
READ NEXT: 12 Best Falling Stocks to Invest In Now and 10 Best 52-Week High US Stocks to Buy.